Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
Effects of Tofacitinib, an Oral Janus Kinase Inhibitor, on Active Ulcerative Colitis | |
|
| |
Ulcerative colitis is a long-term
inflammatory disorder of the large intestine (colon) and rectum. There is no
effective therapy which works in all patients of ulcerative colitis. In a
recent study, tofacitinib (CP-690,550), a selective Janus kinases inhibitor was
evaluated for its effectiveness against ulcerative colitis. By blocking Janus
kinases, the drug inhibits the
inflammatory process of ulcerative colitis.
This multi-center, phase 2 clinical trial was conducted on 194 patients ≥ 18 years with a diagnosis of ulcerative colitis for at least 3 months. Over 8 weeks, the active ulcerative colitis patients were treated with twice-a-day 0.5 mg to 15 mg of tofacitinib or placebo. The main outcome was a reduction in ulcerative colitis activity and rectal bleeding as per the Mayo score, which measures the disease severity on a 0-12 scale. Patients continued to receive oral mesalamine or prednisone daily. Colonoscopy was conducted at 0 and 8 week time-points.
The study results showed that after 8 weeks, ulcerative colitis activity decreased by 32%, 48%, 61%, and 78% in patients treated with 0.5 mg, 3 mg, 10 mg and 15 mg tofacitinib, respectively. A 42% decrease in ulcerative colitis activity was also observed in placebo-treated patients. On the other hand, clinical remission was seen in 13%, 33%, 48%, and 41% of patients receiving 0.5 mg, 3 mg, 10 mg and 15 mg tofacitinib, respectively, while 10% placebo-treatment patients showed clinical remission.
Common serious side-effects of tofacinitib included influenza and nasopharyngitis. Other side effects were a decrease in neutrophil count (a type of white blood cell) and increase in LDL-cholesterol levels.
In conclusion, patients with active moderate or severe ulcerative colitis treated with high doses tofacitinib had a clinical response and clinical remission more frequently than those receiving placebo. The role of tofacitinib in maintenance therapy has not been established. Larger studies are required to establish the benefits and adverse effects of tofacitinib in active ulcerative colitis.
Reference: Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis; William Sandborn et al; N Engl J Med 2012; 367:616-624
Source-Medindia
| |
|
|
More News on: Ulcerative Colitis, Anal Warts, Autoimmune Disorders, Dental Check-Up, Digestive Tract Ulcers Symptom Evaluation
 Comment & Contribute
|
Related Links
Ulcerative Colitis
Ulcerative colitis is characterized by bouts of diarrhea, bleeding per rectum and pain, which remits and relapses. Fulminant colitis is a ...
Colonoscopy Versus Fecal Immunochemical Testing in Colorectal-Cancer
Though fecal immunochemical testing (FIT) is preferred by many for the screening of colorectal cancer, a higher number of precancerous and ...
Health Watch News
How Much Vitamin D is Needed for Infants?
We all know very well that vitamin D or 'the sunshine vitamin' is required for the growth and development of healthy bones. In the initial ...
You Will Invite Hatred by Fat Talk
You might be conscious about being overweight but make a point to avoid talking about your obesity with others, as nobody likes it or is interested ...
Dual Parenting More Beneficial Than Single Parenting, Shows Brain Research
Canadian research suggests that dual parenting may be more beneficial than single parenting. It may offer the advantage of enhancing brain cell ...
Status of Elderly In-Hospital Cardiac Arrest Survivors
It is now well known that cardiac arrest survivors suffer severe emotional and mental stress. The survivors also experience some degree of ...
Outdoor Activity Reduces Chances of Developing Nearsightedness in Kids
Two new studies published in the journal Ophthalmology reveal that spending time outdoors may help prevent or minimize nearsightedness ...
Bone Health in Children Requires Magnesium Along With Calcium
Whenever parents think of bone health of their child, the first thing that comes to their mind is calcium. It looks like magnesium too has an ...
Medwonders Health Network
- Health News Index
|
|
- News Quick Links
 |
Ulcer
Complete Medindia Resources
|
| News Categories: |
| » | Link Between Agent Orange Exposure and Prostate Cancer |
| » | Tumour Growth Mechanism Goes a Step Further |
| » | Link Between Skin Cancer and Lower Risk of Alzheimer's Disease Identified |
| » | Molecular Profiling Timely for Tailoring Therapy Shown By First Prospective Trial |
| » | Broad Support for Rationing of Some Types of Cancer Care Found By Penn Medicine Study |
| More Cancer News | |
|
Ask an Expert
